Everything publicly known about how CagriSema is given comes from the REDEFINE trial protocols and the conference and journal reports of those trials, not from an approved product label. The combination pairs cagrilintide, a long-acting amylin analogue, with semaglutide, a GLP-1 receptor agonist, in one co-formulated once-weekly subcutaneous injection. That distinction between a studied schedule and a prescribing instruction is the frame for every figure below.
Every published CagriSema dosing figure, including the 2.4 mg cagrilintide plus 2.4 mg semaglutide once-weekly maintenance strength reached across a sixteen-week escalation, comes from the REDEFINE trial record rather than from an approved label.
The matching 2.4 mg figures on each side of the combination read like a statement that the two peptides contribute equally, and they are not. 2.4 mg is the established high dose of semaglutide for weight management, and cagrilintide was carried to the same nominal strength in the combination after its own dose-ranging work supported that level.
The maintenance strength studied in the REDEFINE programme is 2.4 mg of cagrilintide co-formulated with 2.4 mg of semaglutide in one weekly injection, a fixed pair that cannot be titrated component by component.
Roughly four months of gradual increase before full strength would look inefficient for most medicines, and here it is the mechanism that makes the class usable at all. Amylin analogues and GLP-1 receptor agonists both slow gastric emptying, and the body adapts to that effect over weeks rather than days. The timeline carries a real cost for anyone weighing it: weight change generally begins during the ramp, but the maintenance period does the bulk of the work.
The registered trial design reaches the 2.4 mg plus 2.4 mg maintenance strength through a stepwise ladder of paired strengths across a sixteen-week escalation period, followed by a fifty-two week maintenance period.
A trial protocol and a product label are different kinds of document with different force, and coverage of trial results tends to blur the two. A protocol records what investigators agreed to do with a screened population under monitoring; a label is a regulator's binding statement of how a medicine may be prescribed to the general population, written only after review of the full submitted dossier. Regulators routinely narrow an indicated population, drop a strength, or add contraindications relative to what was studied, which is where the exposure sits for anyone acting on trial numbers early.
| Criteria | Trial protocol | Approved label |
|---|---|---|
| Force | Agreement among investigators | Regulator's binding statement |
| Population | Screened, eligible participants | General prescribed population |
| Oversight | Scheduled visits, monitoring, investigator intervention | Routine clinical care |
| Status for CagriSema | Published in full | Not issued; submitted, not approved |
CagriSema had been submitted for regulatory review and was not approved for marketing at the time of writing, which means no authoritative dosing text for the combination exists in any country.
Gastrointestinal events are not a footnote in this programme. They reached about four fifths of the combination group against about two fifths on placebo, they cluster around dose increases, and the programme's own answer was the ladder rather than a second drug.
Gastrointestinal events affected roughly four fifths of the combination group against about two fifths on placebo, and the trial design's remedy was the escalation ladder itself, holding or stepping back rather than pushing through.
Combination injectables live or die on whether two molecules stay compatible and stable together in one cartridge at the same pH and concentration, and cagrilintide and semaglutide were developed as a fixed-dose pair because that co-formulation held up. The practical result is a single weekly subcutaneous shot rather than two separate injections.
The public trial record documents a once-weekly subcutaneous injection of one co-formulated solution carrying both peptides, and does not name the delivery device, which becomes firm only with approved packaging and its instructions for use.
Obesity pharmacotherapy in this class is framed as chronic treatment of a chronic condition, and the trial designs are built that way, holding participants at maintenance strength for the remainder of a study running well over a year. The evidence about stopping comes from the wider class rather than from CagriSema itself, and it points one direction: lost weight returns. That shifts the question from how long a course runs to what ongoing therapy costs and requires.
Withdrawal studies across the high-dose GLP-1 class consistently report substantial weight regain and a return of cardiometabolic measures toward baseline within a year of stopping, which is why the class is described as ongoing therapy rather than a course to complete.
Rotation is widely assumed to be about keeping absorption even, and for once-weekly GLP-1 therapy that is not the reason. Absorption from the abdomen, thigh, and upper arm is close enough that the choice usually comes down to reach and comfort, while rotation protects the tissue from months of repeated injection into one square inch.
Absorption from the abdomen, thigh, and upper arm is close enough in weekly GLP-1 therapy that rotation exists to protect the tissue rather than to control drug exposure.
Long-acting weekly peptides are forgiving by design, since their half-lives run in days and blood levels do not collapse the moment a dose is late. No missed-dose rule exists for this combination, so the only documented rules belong to approved high-dose semaglutide, and each one is keyed to how far away the next scheduled dose is.
No missed-dose rule exists for CagriSema itself, and the two-day threshold and the restart-through-escalation option come from approved high-dose semaglutide labelling, which governs that product rather than the combination.
Storage is the part of peptide therapy most often treated as a detail, and it is the one that can quietly destroy the product. Freezing damages the peptide irreversibly, sustained heat does the same more slowly, and neither failure leaves a reliable visual signature. None of it has been confirmed for this combination, since the storage window, in-use period, and disposal guidance all arrive with approved packaging.
Every storage figure here, including the two to eight degree refrigeration range and the limited room-temperature in-use window, is drawn from comparable approved weekly GLP-1 products, because CagriSema has no approved packaging or instructions for use.
Educational use only. This article describes what the published scientific and clinical literature reports about CagriSema. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
